欧洲液体活检市场预测至 2027 年 - COVID-19 影响及产品和服务区域分析（设备、试剂和试剂盒及服务）；样品（血液样品、尿液样品和其他样品）；循环生物标志物（循环肿瘤细胞（CTC）、外泌体和游离核酸）；应用（无创产前检测（NIPT）、肿瘤学、移植诊断和其他应用）；最终用户（学术和研究机构、医院、参考实验室和其他最终用户）；以及，国家
No. of Pages: 148 | Report Code: TIPRE00013007 | Category: Life Sciences
No. of Pages: 148 | Report Code: TIPRE00013007 | Category: Life Sciences
液体活检是一项革命性技术，它开辟了多种视角。该技术包括分离和检测循环肿瘤细胞、循环肿瘤DNA和外泌体，提供癌症患者的基因组信息。液体活检用于癌症诊断，以研究对特定治疗的反应或耐药性。
此外，欧洲肿瘤内科学会 (ESMO) 是肿瘤内科领先的专业组织，正在继续帮助肿瘤学专业人士帮助他们在这种情况下为癌症患者提供最佳护理。 COVID-19 大流行对癌症患者的焦虑、恐惧和心理困扰影响很大。然而，由于 COVID-19 的增长，诊断试剂盒和化验的供应因隔离时间延长和所有业务运营关闭而被推迟。由于该地区感染病例呈指数级增长，欧洲正面临着疫情爆发的巨大影响。根据公开数据，截至3月26日，欧洲地区估计有25万名感染者。此次疫情对意大利、西班牙、德国、法国、英国等国家造成严重打击。
欧洲液体活检市场预计将从2018年的10.176亿美元增至2027年的22.5112亿美元。预计2019-2027年该市场的复合年增长率为9.5%。推动市场增长的因素包括政府和全球卫生组织的举措。然而，液体活检的低敏感性可能会对市场增长产生负面影响。
产品与就服务而言，试剂和试剂盒细分市场在 2018 年欧洲液体活检市场中占据最大市场份额。就样本而言，到 2027 年，基于血液的细分市场在液体活检市场中占据最大市场份额。 2019年，肿瘤细胞（CTC）细分市场在欧洲液体活检市场中占据最大的市场份额。到2027年，肿瘤学细分市场按应用占据最大的市场份额。此外，就最终用户而言，到 2027 年，参考实验室细分市场将占据液体活检市场的最大市场份额。
报告中包含的液体活检市场的一些主要主要和次要来源包括：生物技术和生物科学研究委员会 (BBSRC)、英国外科杂志(BJS)、阿姆斯特丹癌症中心 (CCA)、国际糖尿病联合会 (IDF) 等。
< p>
< strong>按地理位置
• 欧洲
Strategic insights for Europe Liquid Biopsy involve closely monitoring industry trends, consumer behaviours, and competitor actions to identify opportunities for growth. By leveraging data analytics, businesses can anticipate market shifts and make informed decisions that align with evolving customer needs. Understanding these dynamics helps companies adjust their strategies proactively, enhance customer engagement, and strengthen their competitive edge. Building strong relationships with stakeholders and staying agile in response to changes ensures long-term success in any market.
| Report Attribute | Details |
|---|---|
| Market size in 2018 | US$ 1,017.60 Million |
| Market Size by 2027 | US$ 2,251.12 Million |
| Global CAGR (2019 - 2027) | 9.5% |
| Historical Data | 2016-2017 |
| Forecast period | 2019-2027 |
| Segments Covered |
By 产品与服务
|
| Regions and Countries Covered | 欧洲
|
| Market leaders and key company profiles |
The regional scope of Europe Liquid Biopsy refers to the geographical area in which a business operates and competes. Understanding regional nuances, such as local consumer preferences, economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved regions or adapting their offerings to meet regional demands. A clear regional focus allows for more effective resource allocation, targeted marketing, and better positioning against local competitors, ultimately driving growth in those specific areas.
The Europe Liquid Biopsy Market is valued at US$ 1,017.60 Million in 2018, it is projected to reach US$ 2,251.12 Million by 2027.
As per our report Europe Liquid Biopsy Market, the market size is valued at US$ 1,017.60 Million in 2018, projecting it to reach US$ 2,251.12 Million by 2027. This translates to a CAGR of approximately 9.5% during the forecast period.
The Europe Liquid Biopsy Market report typically cover these key segments-
The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the Europe Liquid Biopsy Market report:
The Europe Liquid Biopsy Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:
The Europe Liquid Biopsy Market report is valuable for diverse stakeholders, including:
Essentially, anyone involved in or considering involvement in the Europe Liquid Biopsy Market value chain can benefit from the information contained in a comprehensive market report.
Office No. 1011, First floor, Farena Corporate Park, Magarpatta-Mundhwa road, Pune - 411028, Maharashtra, India
US:+16467917070
sales@businessmarketinsights.com
Get Free Sample For Europe Liquid Biopsy Market
